Charles River Acquires ChanTest
News Oct 31, 2014
Headquartered in Cleveland, Ohio, ChanTest offers a panel of more than 120 validated assays to test ion channels, which we believe is the most comprehensive panel in the industry. ChanTest scientists are thought leaders in the field of ion channels and are currently working with the FDA on the Comprehensive in vitro Proarrhythmia Assay (CiPA) guidelines.
As researchers increasingly incorporate ion channel testing into their molecule design process, access to more comprehensive ion channel assay panels will be invaluable to supporting their drug discovery efforts. With this acquisition, we are emerging as the market-leading CRO in ion channel drug discovery and associated in vitro safety testing.
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE